What stands between people and the drugs they need?
For Tobeka Daki, the price was just too high.
This single mother of two started treatment for aggressive HER2-positive breast cancer in 2013. Along with surgery, radiation and chemotherapy, her oncologist ordered a medicine called trastuzumab.
The World Health Organization recommends it for controlling her type of cancer and it is the standard of care in wealthy countries.
The price charged by the only pharmaceutical corporation selling it within Africa? About US$35,000 per year.
Tobeka tried to get access to the drug. But because the drug was expensive and hard for public health systems to get, her request was denied.
Tobeka never got the trastuzumab she needed. Her cancer returned in 2015. She died the following year.
How MSF is addressing intellectual property barriers
Our medical teams are heavily reliant on affordable generic medicines to treat people in our projects. That's why we work to protect the continued production of generic medicines - in particular from India. Our work includes advocating to remove provisions in international trade deals that could restrict the production of generic medicines.
We mobilise alongside other civil society groups in many places to bring attention to this issue under the umbrella of our ‘Hands Off our Medicines’ campaign. Recent activities have focussed on the Trans Pacific Partnership agreement, and the Regional Comprehensive Economic Partnership talks.
Take a closer look
Novartis and “Drop the Case”: defending a key source of generic drugs
India is sometimes called “the pharmacy of the developing world,” because it manufactures so many affordable generic medicines relied on by millions of people around t